Contract Biomanufacturing Services Global Market Forecast to 2025 [Report Updated: 17082017] Prices from USD $3600

12:56 EDT 18 Aug 2017 | BioPortfolio Report Blog

The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $36.6 billion by 2025.
Biomanufacturing is a widely used term to describe manufacture of biologic molecules for various stages of drug development right from preclinical stage to commercial supply. The biologic drug manufacturing is a complex process involving huge capital and sound technical expertise. Many large and small pharmaceutical companies are turning to outsourcing the drug manufacture process to reduce capital investments on capacities and focus more on their core competencies. Contract manufacturing organizations, particularly for RD and clinical trials, are making product manufacture, more efficient and often less costly. In addition to that, the use of singleuse bioreactors is effectively reducing the manufacture facility cost. This option is more viable for smaller and lowfunded companies for their inhouse candidate product manufacturing needs, whereby, the companies can avoid $50$150 million facility costs for construction of fixed, dedicated stainless steel bioreactorbased bioprocessing systems and outsource their manufacturing requirements to CMOs which use singleuse facilities which typically cost $25$40 million for commercial manufacture.
There is a continued growth of biopharmaceutical market which is expected to nearly double in next 10 years. This will be a result of continued new product approvals, expansion of indications for current products which include lessdeveloped countries becoming more affluent and increased drug demand of the aging population in the U.S. and other major pharmaceutical markets. Aging populations are at a high risk of developing chronic diseases such as cancer and arthritis and these diseases are being precisely targeted using biopharmaceuticals. Many blockbuster drugs losing their exclusivity are also giving room for many biosimilar and biobetters companies to enter into the world's biopharmaceuticals market subsequently attracting many CROs, CDMOs, and CMOs to enter into the picture. Hence, there is every reason to assume that future growth in biopharmaceutical outsourcing will continue at a minimum X% in western countries to about X% in Asian countries.
Nowadays CMOs are gaining much prominence due to increased demand for the clinical and commercial supply of biologics. Such prominence is achieved mainly through capacity expansions or more easily through mergers and acquisitions. In September 2016, Asahi Glass, a Japanese manufacturer of glass, chemicals, and hightech materials acquired a leading European bioCMO, Biomeva Holding GmbH to expand their life science business and expand into newer geographies. Contract manufacturing services are mainly benefitting the small scale companies which lack the facilities for the biomanufacturing and also intend to not invest in fixed assets like steel bioreactors and bioprocessing facilities thus giving opportunity for the CMOs to gain market presence.
The contract biomanufacturing global market is dominated by North America which contributes to revenue of $XX billion in 2016 growing at a CAGR of X% according to IQ4I estimation. The Asia Pacific region is witnessing huge growth opportunities in terms of biologics outsourcing and many local contract manufacturing organizations are taking the lead in making this region the most sought after destination for biologics outsourcing. Some of the reasons why countries such as China and India are favourite destinations for such projects include the lower cost of labour, higher technical expertise and favourable government regulations in countries such as China. The Asia Pacific region is valued at $X billion in 2016 and is expected to grow at a strong X% CAGR from 20162025 reaching $X billion by 2025.
The global biomanufacturing outsourcing market is driven by factors such as globalization of biomanufacturing facilities, increased funding from private venture capitals and government organizations, increasing outsourcing budgets and emergence of latest technologies such as singleuse bioreactors. Increased funding has been seen as a boon for Chinese CMOs for becoming a lucrative market for biomanufacturing outsourcing. An example of such funding includes Autek Bio who raised an impressive $100 million for building Asia's largest CMO facility in south Beijing from private and government sources. There are restraints and threats as well which could potentially hamper the biomanufacturing outsourcing market. These include unequal distribution of biomanufacturing capacities around the globe which could pose capacity constrains in future, Stringent regulatory affairs and mandatory cGMP certifications which could make the drug manufacture process to further low down, outsourcing being restricted to only small and midsized companies are another major restraint where large companies are looking for CMOs as an option only when there are insufficient capabilities internally.

Original Article: Contract Biomanufacturing Services Global Market Forecast to 2025 [Report Updated: 17082017] Prices from USD $3600


More From BioPortfolio on "Contract Biomanufacturing Services Global Market Forecast to 2025 [Report Updated: 17082017] Prices from USD $3600"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...